B. Löwenberg
Löwenberg, Bob, 1946-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Löwenberg, B. (Bob), 1946-
Löwenberg, Bob
Löwenberg, B. (Bob)
VIAF ID: 84865347 (Personal)
Permalink: http://viaf.org/viaf/84865347
Preferred Forms
-
100 0 _
‡a
B. Löwenberg
-
200 _ |
‡a
Löwenberg
‡b
Bob
-
100 1 0
‡a
Löwenberg, B.
‡q
(Bob),
‡d
1946-
-
100 1 _ ‡a Löwenberg, B. ‡q (Bob), ‡d 1946-
-
100 1 _ ‡a Löwenberg, B. ‡q (Bob), ‡d 1946-
-
100 1 _ ‡a Löwenberg, B. ‡q (Bob), ‡d 1946-
-
100 1 _
‡a
Löwenberg, Bob
-
100 1 _ ‡a Löwenberg, Bob, ‡d 1946-
-
100 1 _
‡a
Löwenberg, Bob,
‡d
1946-....
-
100 1 _
‡a
Löwenberg, B.
‡q
(Bob)
-
100 1 _ ‡a Löwenberg, B. ‡q (Bob), ‡d 1946-
-
100 1 _ ‡a Löwenberg, Bob
-
100 1 _ ‡a Löwenberg, Bob ‡d (1946- ).
-
100 1 _
‡a
Löwenberg, Bob,
‡d
1946-
4xx's: Alternate Name Forms (10)
5xx's: Related Names (2)
- 551 _ _
‡a
Rotterdam
‡4
ortw
‡4
https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _
‡a
Universitair Medisch Centrum
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
Works
| Title | Sources |
|---|---|
| Bone marrow transplantation : biological mechanisms and clinical practice |
|
| Cytokines and growth factors in blood transfusion : proceedings of the Twentyfirst International Symposium Blood Transfusion, Groningen 1996, organised by the Red Cross Blood Bank Noord Nederland |
|
| Erop of eronder : financiering van (bio)medisch wetenschappelijk onderzoek : advies |
|
| Fetal liver cell transplantation : role and nature of the fetal haemopoietic stem cell |
|
| Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug |
|
| Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha |
|
| Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol |
|
| Hierarchical Bayesian formulations for selecting variables in regression models |
|
| High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome |
|
| How I treat : a compendium for the practicing hematologist |
|
| Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia |
|
| The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia |
|
| Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study |
|
| Impaired recovery of Epstein-Barr virus |
|
| Including historical data in the analysis of clinical trials: Is it worth the effort? |
|
| Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants |
|
| Introduction to the review series on leukemic stem cells. |
|
| Keratinocyte growth factor improves allogeneic bone marrow engraftment through a CD4+Foxp3+ regulatory T cell-dependent mechanism |
|
| Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites |
|
| Leerboek hematologie |
|
| Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia |
|
| Low expression of MDS1-EVI1–like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia |
|
| Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet |
|
| MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML |
|
| Minimal residual disease in acute leukemia, 1984: |
|
| MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice |
|
| miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia |
|
| Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. |
|
| MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia |
|
| Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia |
|
| Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways |
|
| Opkomst van Novantrone (mitoxantron) in de oncologie : symposium, Zeist, 26 oktober 1990 |
|
| Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients |
|
| Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cells |
|
| PBX3 is an important cofactor of HOXA9 in leukemogenesis |
|
| The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner |
|
| Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia |
|
| Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia |
|
| Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling |
|
| Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation |
|
| PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells |
|
| Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia |
|
| Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. |
|
| Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? |
|
| Retroviral integration mutagenesis in mice and comparative analysis in human AML identify reduced PTP4A3 expression as a prognostic indicator |
|
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia |
|
| Sense and nonsense of high-dose cytarabine for acute myeloid leukemia |
|
| A series of reviews on "Hematologic Disease at Older Age". |
|
| Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients |
|
| SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels |
|
| Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells |
|
| A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. |
|
| Strict infection control measures do not prevent clonal spread of coagulase negative staphylococci colonizing central venous catheters in neutropenic hemato-oncologic patients |
|
| Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials |
|
| Sustainability and affordability of cancer drugs: a novel pricing model |
|
| Textbook of malignant hematology |
|
| Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. |
|
| Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy |
|
| Translational control of putative protooncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling |
|
| Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors |
|
| Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. |
|
| The value of alloantibody detection in predicting response to HLA-matched platelet transfusions |
|
| The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. |
|
| The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis |
|
| Van de brug af gezien |
|
| A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia |
|
| Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial |
|
| সংশোধন |
|
